Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Reflections

Cell surface antigens: invaluable landmarks reflecting the nature of cells

Toshitada Takahashi and Hiroshi Shiku
Toshitada Takahashi
1Comprehensive Health Science Center, Aichi Health Promotion Foundation, Higashiura Town, Aichi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: t.toshi@festa.ocn.ne.jp
Hiroshi Shiku
2Department of Cancer Vaccine and Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2012
  • Article
  • Info & Metrics
  • PDF
Loading

This article was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

Although Lloyd J. Old was involved in various studies of the interactions between cancer and the immune system, it seems to us that his ideas often originated from the studies of serological identification of mouse lymphocyte antigens. The findings from these studies allow us to distinguish cells of different lineages and differentiation stages, and also to distinguish leukemia cells from normal lymphocytes (1). It is amazing that essentially a single serological technique, i.e., the Trypan blue exclusion test (presumably introduced in Peter Gorer’s laboratory by Edward A. Boyse), was used to define a series of these antigens. This technique was used in conjunction with absorption analysis to elucidate the specificity of antisera, based on a vast knowledge of mouse immunogenetics. In the laboratory, Elisabeth Stockert (who was a technical assistant at that time) was the great master of these serological techniques, carrying out her own projects of cell surface antigens, as will be described below, while managing the day-to-day business of the laboratory. Similarly, Elizabeth A. Carswell and Gayla Geering investigated tumor necrosis factor (TNF) and retrovirus-associated intracellular antigens, respectively, while working as technical assistants.

When Toshitada Takahashi left Nagoya, Japan, for New York in 1968, the TL and Lyt (Ly) series of antigens of thymocytes and peripheral T cells had already been identified by Drs. Old, Boyse, and Stockert (1–3), and congenic strains of mice for each antigen system had been established. Contemporaneously, Katsuaki Itakura was preparing to initiate genetic linkage studies of these differentiation antigens. In the late 1960s, the concept of T cells and B cells was becoming more and more widespread, and after the First International Immunology Congress in Washington, D.C., in 1971, this concept became widely accepted all over the world. The Thy-1 (Θ, CD90) and Lyt series of antigens are considered to be markers for thymocytes and peripheral T cells, whereas TL is a marker for thymocytes. Thus, Takahashi’s project was focused on B cells. When he started his study on cell surface antigen analysis of plasma cell leukemias (PCL), Yoshiyuki Hashimoto kindly taught him how to carry out day-to-day experiments. At that time, Dr. Hashimoto was a visiting investigator from the Biochemistry Institute in Tokyo, Japan, working on cell-mediated immunity against TL-positive leukemias. It is noteworthy that, as the founder of the Japanese Association of Cancer Immunology, Dr. Hashimoto greatly contributed to the progress in tumor immunology in Japan. Dr. Takahashi defined a novel PC.1 alloantigen that is expressed on PCL cells and mature antibody-forming cells (IgG type hemolytic plaque-forming cell, IgG-PFC), but not on peripheral B cells (4). Furthermore, he demonstrated reciprocal expression of surface immunoglobulin, which is expressed on peripheral B cells, but on neither IgG-PFC nor PCL cells. We had to wait until 1973 to see the first report of a B cell alloantigen by Hidetoshi Sato (5), although it is named Lyb-2 (CD72). This protein was later shown to be a ligand for Lyt-1 (CD5) and appears to be present on all B lymphocytes except for plasma cells.

In 1973, Hiroshi Shiku, also from Nagoya, went to the Sloan-Kettering Institute for Cancer Research (SKI) and started working on cell-mediated immunity with Herbert F. Oettgen and Michael A. Bean. Although the chromium release assay had already been established by Cerottini et al. and was widely used to target suspension cells, this assay was not always suitable for monolayer cell cultures derived from solid tumors. In order to detect killing activity against attached target cells, Dr. Bean developed a new microassay using [3H]proline for labeling, instead of chromium 51; this assay was used by Dr. Shiku for his phenotype analysis of T cell subpopulations. A very exciting result was obtained in 1975, namely, that the killer T cell population is relatively rich in Lyt-2/3 (CD8) surface antigens, but relatively poor in Lyt-1 antigen, suggesting that T cells with different functions could be distinguished on the basis of their Lyt phenotypes (6). Subsequently, Eiichi Nakayama clearly demonstrated selective blocking of cytotoxic cells by Lyt-2 and Lyt-3 antisera in vitro in the absence of complement, suggesting that Lyt-2/3 determinants on the surface of cytotoxic T cells have a close spatial relationship to the T cell receptor (7, 8). Furthermore, it was shown later by Drs. Nakayama and Akiko Uenaka in Japan that in vivo administration of Lyt-2/3 antibodies is able to block the cytotoxicity of killer T cells responsible for tumor rejection (9). Thus, Lyt-2/3 was demonstrated to be not merely the marker of killer T cells, but a molecule that is important to their key function. As for the phenotype of effector cells (Th1) and regulatory T cells (Treg), Shimon Sakaguchi and his colleagues demonstrated in 1982 that both populations express Lyt-1, but not Lyt-2/3, i.e., the CD4 phenotype (10, 11); they accomplished this by analysis of an organ-localized autoimmune disease model that develops in mice thymectomized on day 3 after birth. It is now well known that CD8 and CD4 molecules are involved, respectively, in the interactions between T cell receptor and target antigen peptides presented on major histocompatibility complex (MHC) class I and class II molecules. This research laid the groundwork for identifying the cell surface markers that allow cells to be experimentally and diagnostically separated and distinguished, revolutionizing immunology and medicine as it is practiced today.

Unlike the Lyt series of antigens, the TL antigen system has unique characteristics, e.g., TL expression is restricted to thymocytes in certain (TL+) strains of the mouse, indicating a character of differentiation antigens, whereas TL appears in a proportion of T cell leukemias (lymphomas) developed even in TL− strains that normally never express TL during fetal or adult life; these can be regarded as leukemia-specific antigens. Yuichi Obata, who worked with Dr. Old for 12 years, succeeded in 1985 in cloning genomic TL genes as members of MHC genes of chromosome 17 (12). These may be regarded as the first set of cloned genes encoding tumor antigen; the P815 mast cell tumor antigen gene, P1A, was reported by Boon’s group in 1991. In 1985, Dr. Obata then returned to Japan to be a staff member at the Aichi Cancer Center Research Institute in Nagoya, where he continued his TL project. One of the interesting findings obtained thereafter is that when a chemical carcinogen (NBU) was administered to C57BL/6 and C3H strains, T cell leukemia development was slower than in T3B-TL gene-transduced counterpart strains expressing TL ubiquitously as self antigens, suggesting that anti-TL immunity may play a protective role in immune surveillance (13). Another important finding is that immunization with TL-positive skin from T3B-TL transgenic mice produced cytotoxic T cells exhibiting TL- (but not H-2-) restriction (14). This indicated that TL antigen is a transplantation antigen, although in the 1970s it was considered to be a serologically defined antigen.

In the late 1960s and early 1970s, cancer research focused on viral carcinogenesis, since the Epstein-Barr virus (EBV) had been discovered as a candidate for human tumor virus, while retroviruses such as murine leukemia virus (MuLV) and murine mammary tumor virus (MTV) had been shown to be associated with development of murine leukemia and mammary tumor, respectively. In Dr. Old’s laboratory, cell surface and intracellular antigens of MuLV and MTV were extensively studied, and many antigenic systems were defined. Particularly, detailed analyses of the relationship between gp70 of MuLV classes and cell surface antigens were conducted by Drs. Stockert and Obata (15–18). Four antigens were defined as markers for each of the MuLV classes: GIX and G(RADAI) distinguished two types of ecotropic MuLV; G(ERLD) identified all xenotropic MuLV; and G(AKSL2) served as a marker for dual-tropic viruses in high-leukemia strains such as AKR mice. GIX antigen has characteristics of a differentiation antigen and is expressed on thymocytes in low-leukemia strains such as 129 mice; a linkage study conducted by Hisami Ikeda demonstrated that the antigen expression is controlled by linkage group 8 on chromosome 4 (19). During the course of these studies, Kouhei Kawashima obtained an interesting finding: thymocytes exhibit amplified expression of gp70-associated antigens during the late preleukemic period in the AKR strain, which is accompanied by the emergence of MuLVs with dual-tropic (but not ecotropic) properties (20, 21), leading to the belief that dual-tropic MuLVs are the proximal vectors of leukemogenesis in the AKR strain.

In addition to the studies of leukemia, an attempt was also made to detect individual antigens of chemically induced mouse sarcomas by use of the complement-dependent cytotoxicity microassay. The presence of such antigens was demonstrated in the 1960s by in vivo transplantation experiments, but the nature of the antigens was not well understood. In 1977, Albert B. DeLeo produced antisera that detected antigens with an exceedingly restricted distribution on two BALB/c methylcholanthrene-induced sarcomas, Meth A and CMS4 (22). During the course of these studies, he defined a transformation-related intracellular antigen of sarcomas and leukemias with a molecular weight of 53 kilodaltons (23); this antigen is now known to be the product of the p53 tumor suppressor gene. Two genes encoding for individual transplantation antigens detected by cytotoxic T cells were subsequently isolated in Japan from different tumors: RAMP (exon extension mutation) from Meth A, by Dr. Nakayama in 2003 (24), and ERK2 (point mutation) from another sarcoma, CMS5, by Hiroaki Ikeda et al. in 1997 (25). To date, the relationship between these gene products and the serologically defined antigens has not been elucidated.

Here, we have only introduced a part of the mouse cell surface antigen studies initiated at SKI, and briefly discussed their further development in Japan. It is noteworthy that not only genes encoding these antigens, but also fertilized eggs of the pertinent congenic and transgenic mouse strains are maintained even now at the BioResource Center of Riken Tsukuba Institute (director, Dr. Obata), and are available to researchers interested in this field.

  • © 2012 by Toshitada Takahashi

References

  1. 1.↵
    1. Old LJ
    . Cancer immunology: The search for specificity—G.H.A. Clowes Memorial lecture. Cancer Res 1981;41:361–375.pmid:7004632
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Boyse EA,
    2. Old LJ
    . Some aspects of normal and abnormal cell surface genetics. Annu Rev Genet 1969;3:269–290.(PMID: not available)
    OpenUrlCrossRef
  3. 3.↵
    1. Old LJ,
    2. Stockert E
    . Immunogenetics of cell surface antigens of mouse leukemia. Annu Rev Genet 1977;11:127–160.pmid:202188
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Takahashi T,
    2. Old LJ,
    3. McIntire KR,
    4. Boyse EA
    . Immunoglobulin and other surface antigens of cells of the immune system. J Exp Med 1971;134:815–832.pmid:4106485
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Shiku H,
    2. Kisielow P,
    3. Bean MA,
    4. Takahashi T,
    5. Boyse EA,
    6. Oettgen HF,
    7. Old LJ
    . Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med 1975;147:227–241.pmid:1078839
    OpenUrlPubMed
  6. 6.↵
    1. Sato H,
    2. Boyse EA
    . A new alloantigen expressed selectively on B cells: the Lyb-2 system. Immunogenetics 1976;3:565–572.(PMID: not available)
    OpenUrlCrossRef
  7. 7.↵
    1. Nakayama E,
    2. Shiku H,
    3. Stockert E,
    4. Oettgen HF,
    5. Old LJ
    . Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. Proc Natl Acad Sci U S A 1979;76:1977–1981.pmid:88050
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Nakayama E,
    2. Dippold W,
    3. Shiku H,
    4. Oettgen HF,
    5. Old LJ
    . Alloantigen-induced T-cell proliferation: Lyt phenotype of responding cells and blocking of proliferation by Lyt antisera. Proc Natl Acad Sci U S A 1980;77:2890–2894.pmid:6967215
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Nakayama E,
    2. Uenaka A
    . Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection. J Exp Med 1985;161:345–355.pmid:3871834
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Sakaguchi S,
    2. Takahashi T,
    3. Nishizuka Y
    . Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer. J Exp Med 1982;156:1565–1576.pmid:6983557
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Sakaguchi S,
    2. Takahashi T,
    3. Nishizuka Y
    . Study on cellular events in postthymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. J Exp Med 1982;156:1577–1586.pmid:6983558
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Obata Y,
    2. Chen YT,
    3. Stockert E,
    4. Old LJ
    . Structural analysis of TL genes of the mouse. Proc Natl Acad Sci U S A 1985;82:5475–5479.pmid:2410925
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Tsujimura K,
    2. Obata Y,
    3. Matsudaira Y,
    4. Ozeki S,
    5. Nishida K,
    6. Okanami Y,
    7. Akatsuka Y,
    8. Kuzushima K,
    9. Takahashi T
    . Immunity against mouse thymus-leukemia antigen (TL) protects against development of T lymphomas induced by a chemical carcinogenic agent, N-butyl-N-nitrosourea. Cancer Sci 2004;95:914–919.pmid:1554651
    OpenUrlPubMed
  14. 14.↵
    1. Tsujimura K,
    2. Obata Y,
    3. Takahashi T
    . Thymus-leukemia antigen (TL) as a major histocompatibility complex (MHC) class Ib molecule and tumor-specific antigen. Cancer Sci 2004;95:469–474.pmid:15182425
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Stockert E,
    2. Old LJ,
    3. Boyse EA
    . The G-IX system. A cell surface alloantigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J Exp Med 1971;133:1334–1355.pmid:5576334
    OpenUrlAbstract
  16. 16.
    1. Obata Y,
    2. Stockert E,
    3. O’Donnell PV,
    4. Okubo S,
    5. Synder HW Jr.,
    6. Old LJ
    . G(RADA1): a new cell surface antigen of mouse leukemia defined by naturally occurring antibody and its relationship to murine leukemia virus. J Exp Med 1978;147:1089–1105.pmid:206645
    OpenUrlAbstract/FREE Full Text
  17. 17.
    1. Stockert E,
    2. DeLeo AB,
    3. O’Donnell PV,
    4. Obata Y,
    5. Old LJ
    . G(AKSL2): a new cell surface antigen of the mouse related to the dualtropic mink cell focus-inducing class of murine leukemia virus detected by naturally occurring antibody. J Exp Med 1979;149:200–215.pmid:216764
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Obata Y,
    2. Stockert E,
    3. DeLeo AB,
    4. O’Donnell PV,
    5. Snyder HW Jr.,
    6. Old LJ
    . A cell surface antigen of the mouse related to xenotropic MuLv defined by naturally occurring antibody and monoclonal antibody. Relation to Gix G(rada1), G(aksl2) systems of MuLV-related antigens. J Exp Med 1981;154:659–675.pmid:6268731
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Ikeda H,
    2. Stockert E,
    3. Rowe WP,
    4. Boyse EA,
    5. Lilly F,
    6. Sato H,
    7. Jacobs S,
    8. Old LJ
    . Relation of chromosome 4 (linkage group 8) to murine leukemia virus-associated antigens of AKR mice. J Exp Med 1973;137:1103–1107.pmid:4348279
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Kawashima K,
    2. Ikeda H,
    3. Hartley JW,
    4. Stockert E,
    5. Rowe WP,
    6. Old LJ
    . Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A 1976;73:4680–4684.pmid:188051
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Kawashima K,
    2. Ikeda H,
    3. Stockert E,
    4. Takahashi T,
    5. Old LJ
    . Age-related changes in cell surface antigens of preleukemic AKR thymocytes. J Exp Med 1976;144:193–208.pmid:180229
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. DeLeo AB,
    2. Shiku H,
    3. Takahashi T,
    4. John M,
    5. Old LJ
    . Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J Exp Med 1977;146:720–734.pmid:197192
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. DeLeo AB,
    2. Jay G,
    3. Appella E,
    4. Dubois GC,
    5. Law LW,
    6. Old LJ
    . Detection of a transformation-related antigen in chemically induced sarcoma and other transformed cells of the mouse. Proc Natl Acad Sci U S A 1979;76:2420–2424.pmid:221923
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Uenaka A,
    2. Nakayama E
    . Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL) Cancer Sci 2003;94:931–936.pmid:14611667
    OpenUrlPubMed
  25. 25.↵
    1. Ikeda H,
    2. Ohta N,
    3. Furukawa K,
    4. Miyazaki H,
    5. Wang L,
    6. Kuribayashi K,
    7. Old LJ,
    8. Shiku H
    . Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc Natl Acad Sci U S A 1997;94:6375–6379.pmid:9177225
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Cancer Immunity Archive: 12 (1)
January 2012
Volume 12, Issue 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cell surface antigens: invaluable landmarks reflecting the nature of cells
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cell surface antigens: invaluable landmarks reflecting the nature of cells
Toshitada Takahashi and Hiroshi Shiku
Cancer Immun January 1 2012 (12) (1) 2;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cell surface antigens: invaluable landmarks reflecting the nature of cells
Toshitada Takahashi and Hiroshi Shiku
Cancer Immun January 1 2012 (12) (1) 2;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The discovery of Cancer/Testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines
  • “But Dr. Old, we already have an antibody!” Reflections on Lloyd Old’s “academic biotech” approach for targeted antibodies
  • Autologous typing: a tedious but orthodox approach for defining human tumor antigens with clarity
Show more Reflections
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement